Intensified Adjuvant Treatment of Prostate Carcinoma: Feasibility Analysis of a Phase I/II Trial

Table 2

Patients and treatment characteristics.

	Number	%
All patients	123	100
Age (median, range), years	64, 46–78
pT
1c	0	0
2a	1	0.8
2b	2	1.6
2c	14	11.4
3a	61	49.6
3b	41	33.3
4	4	3.3
pN
0	79	64.2
1	18	14.6
𝑋	26	21.1
Perineural infiltration
No	47	38.2
Yes	76	61.8
PSA before surgery (median, range), μg/L	8.8, 0.4–55.0
PSA after surgery (median, range), μg/L	0.06, 0.01–0.90
Histopathologic grade, Gleason score
2–6	23	18.7
7	69	56.1
8–10	31	25.2
Lymphadenectomy
No	26	21.1
Yes	97	78.9
Interval surgery-radiotherapy (median, range), months	4 (2–9)
Radiotherapy dose to prostatic bed, Gy
64.8	18	14.6
70.2	105	85.4
Elective nodal irradiation
No	52	42.3
Yes	71	57.7
Adjuvant hormonal therapy
No	38	30.9
Bicalutamide	48	39.0
LH-RH analogue	37	30.1